Molecular topology analysis of the differences between drugs, clinical candidate compounds, and bioactive molecules

Journal of Chemical Information and Modeling

Volumn 50, Issue 12, 2010, Pages 2141-2150

  Chen, Hongming ^a   Yang, Yidong ^a   Engkvist, Ola ^a  

^a ASTRAZENECA R AND D   (Sweden)

Author keywords

[No Author keywords available]

Indexed keywords

TOPOLOGY;

BIOACTIVE COMPOUNDS; BIOACTIVE MOLECULES; MOLECULAR BRIDGES; MOLECULAR FRAMEWORKS; MOLECULAR SIZE; MOLECULAR TOPOLOGIES; ONE-RING SYSTEMS; POTENTIAL PROTEINS;

MOLECULES;

DRUG;

ARTICLE; CHEMISTRY; CLASSIFICATION; COMPARATIVE STUDY; HUMAN; PHARMACOLOGY;

HUMANS; PHARMACEUTICAL PREPARATIONS; PHARMACOLOGY;

EID: 78650699097     PISSN: 15499596     EISSN: 1549960X     Source Type: Journal    
DOI: 10.1021/ci1002558     Document Type: Article

References (22)

1. Lipinski, C. A.; Lombardo, F.; Dominy, B. W.; Feeney, P. J. Experimental and computational approaches to estimate solubility and permeability in drug discovery and development settings Adv. Drug Delivery Rev. 1997, 23, 3-25
2. Oprea, T. I.; Davis, A. M.; Teague, S. J.; Leeson, P. D. Is there a difference between leads and drugs? A historical perspective J. Chem. Inf. Comput. Sci. 2001, 41, 1308-35
3. Wenlock, M. C.; Austin, R. P.; Barton, P.; Davis, A. M.; Leeson, P. D. A comparison of physiochemical property profiles of development and marketed oral drugs J. Med. Chem. 2003, 46, 1250-1256
4. Vieth, M.; Sutherland, J. J. Dependence of molecular properties on proteomic family for marketed oral drugs J. Med. Chem. 2006, 49, 3451-3453
5. Tyrchan, C.; Blomberg, N.; Engkvist, O.; Kogej, T.; Muresan, S. Physicochemical property profiles of marketed drugs, clinical candidates and bioactive compounds Bioorg. Med. Chem. Lett. 2009, 19, 6943-6947
6. Leeson, P. D.; Springthorpe, B. The influence of drug-like concepts on decision-making in medicinal chemistry Nat. Rev. Drug Discovery 2007, 6, 881-890
7. Lovering, F.; Bikker, J.; Humblet, C. Escape from Flatland: Increasing saturation as an approach to improving clinical success J. Med. Chem. 2009, 52, 6752-6756
8. Ritchie, T. J.; Macdonald, S. J. The impact of aromatic ring count on compound developability-Are too many aromatic rings a liability in drug design Drug Discovery Today 2009, 14, 1011-1020
9. Bemis, G. W.; Murcko, M. A. The properties of known drugs. 1. Molecular Frameworks J. Med. Chem. 1996, 39, 2887-2893
10. Grabowski, K.; Schneider, G. Properties and architecture of drugs and natural products revisited Curr. Chem. Biol. 2007, 1, 115-127
11. Lee, M. L.; Schneider, G. Scaffold architecture and pharmacophoric properties of natural products and trade drugs: Application in the design of natural product-based combinatorial libraries J. Comb. Chem. 2001, 3, 284-289
12. Hu, Y.; Bajorath, J. Scaffold distributions in bioactive molecules, clinical trials compounds, and drugs ChemMedChem 2009, 5, 187-190
13. Wang, J.; Hou, T. Drug and drug candidate building block analysis J. Chem. Inf. Model. 2010, 50, 55-67
14. Xu, Y. J.; Johnson, M. Algorithm for naming molecular equivalence classes represented by labeled pseudographs J. Chem. Inf. Comput. Sci. 2001, 41, 181-185
15. Xu, Y. J.; Johnson, M. Using molecular equivalence numbers to visually explore structural features that distinguish chemical libraries J. Chem. Inf. Comput. Sci. 2002, 42, 912-926
16. GVKBio databases 2009; GVK Biosciences Private Ltd.: Hyderabad, India, 2009.
17. BioByte ClogP, version 4.3, http://www.biobyte.com (accessed Feb. 20, 2010).
18. Pipeline Pilot, version 7.5; Accelrys: San Diego, CA.
19. OEChem toolkit 1.7.2; OpenEye Scientific Software, Inc.: Santa Fe, NM.
20. Sorkau, E. Ringerkennung in chemischen Strukturen mit dem Computer Wiss. 2. Tech. Hochsch. Leuna-Meuseburg. 1985, 27, 765-770
21. JMP, version 7.0; SAS Institute Inc.: Cary, NC.
22. Yang, Y.; Chen, H.; Nilsson, I.; Sorel, M.; Engkvist, O. Investigation of the relationship between the topology and selectivity for druglike molecules J. Med. Chem. 2010, 53 (21) 7709-7714